Alkem Analyst Rating
based on 21 analysts
42.86%
Buy
33.33%
Hold
23.81%
Sell
Based on 21 analysts offering long term price targets for Alkem. An average target of ₹5777.67
Source: S&P Global Market Intelligence
Alkem Share analysis
Alkem price forecast by 21 analysts
Upside of9.93%
High
₹7225
Target
₹5777.67
Low
₹4330
Alkem target price ₹5777.67, a slight upside of 9.93% compared to current price of ₹5255.85. According to 21 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Alkem revenue growth forecast
Expected growth rate Q1, FY2027:27.53%
Forecast
Actual
Including amortisation and stock based compensations
Alkem EPS growth forecast
EPS estimate Q1, FY2027:51.20%
Forecast
Actual
Source: S&P Global Market Intelligence
Alkem Performance
Day's Low
Day's High
₹5,166.5Day's Price Range₹5,283.552 Week's Low
52 Week's High
₹4,407.0552-Week Price Range₹6,439.9
| Returns % | |
| 1 Month Return | -4.32 % |
| 3 Month Return | -14.3 % |
| 1 Year Return | + 6.53 % |
| Market Stats | |
| Previous Close | ₹5,181.80 |
| Open | ₹5,192.00 |
| Volume | 74.86K |
| Upper Circuit | - |
| Lower Circuit | - |
| Market Cap | ₹61,956.19Cr |
Alkem Key Statistics
| P/E Ratio | 29.61 |
| PEG Ratio | 0.51 |
| Market Cap | ₹61,956.19 Cr |
| P/B Ratio | 5.6 |
| EPS | 151.52 |
| Dividend Yield | 0.81 |
| Sector | Pharmaceuticals |
| ROE | 17.56 |
Alkem Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| HOLD | ₹61,956.19 Cr | 24.55% | 0.56 | ₹1,811 Cr | ₹12,667 Cr | |
| HOLD | ₹23,516.99 Cr | 14.04% | 0.55 | ₹362 Cr | ₹2,226 Cr | |
| HOLD | ₹30,074.31 Cr | 120.86% | 0.67 | ₹168 Cr | ₹5,040 Cr | |
| BUY | ₹11,607.39 Cr | 14.91% | 0.64 | ₹119 Cr | ₹547 Cr | |
| BUY | ₹4,315.65 Cr | 10.84% | 0.54 | ₹69 Cr | ₹571 Cr |
About Alkem
With its headquarters in Mumbai, India, Alkem Laboratories is engaged in the manufacture of a wide range of pharmaceutical products across multiple therapeutic categories, including cardiovascular, central nervous system, gastro-intestinal, anti-infective, diabetology, and nutrition. The company has a strong presence in the Indian market and exports its products to over 50 countries.
Share Price: ₹5255.85 per share as on 17 Jan, 2025 04:01 PM
Market Capitalisation: ₹61,956.19Cr as of today
Revenue: ₹3,414.67Cr as on September 2024 (Q3 24)
Net Profit: ₹701.96Cr as on September 2024 (Q3 24)
Listing date: 23 Dec, 2015
Chairperson Name: Basudeo N Singh
| Organisation | Alkem |
| Headquarters | Mumbai |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
Key events for Alkem Laboratories Ltd
Alkem Sells Pithampur Facility to Rubicon Research - 07 Jan, 2025
Alkem Laboratories Ltd has agreed to sell its manufacturing facility in Pithampur, Madhya Pradesh, to Rubicon Research Ltd for Rs 149 crore. This strategic move aims to optimize operations and enhance efficiency.Alkem Laboratories Reports Q2 Profit Growth - 25 Dec, 2024
Alkem Laboratories' consolidated net profit rose 14% to Rs 702 crores in Q2, driven by increased other income. Revenue slightly declined by 0.7% to Rs 3,415 crores, while domestic sales grew by 5.7%, reflecting a stronger focus on the domestic market.Alkem Laboratories Invests in Renewable Energy Project - 18 Dec, 2024
Alkem Laboratories, along with its subsidiary Enzene Biosciences, has signed an agreement to acquire a 26% stake in Sunsure Solarpark for Rs 1.95 crore, enhancing its renewable energy portfolio.Promoter Group Member Makes Luxury Purchase Amid Share Sale - 13 Dec, 2024
Seema Singh, part of Alkem Laboratories' promoter group, purchased a luxury apartment for Rs 185 crore after divesting over 3.58 lakh shares worth Rs 177 crore.Alkem Transfers Trade Generics Business to Subsidiary - 10 Dec, 2024
Alkem Laboratories has approved the transfer of its trade generics business to its wholly owned subsidiary, Alkem Wellness, for up to ₹750 crore. The transaction aims to enhance business agility and market penetration, with completion expected by March 31, 2025.
Insights on Alkem Laboratories Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTProfit Spike
Netprofit is up for the last 3 quarters, 293.56 Cr → 688.64 Cr (in ₹), with an average increase of 33.5% per quarter
- POSITIVE IMPACT
FII Holding Up
Foreign Institutions have increased holdings from 8.69% to 9.02% in Sep 2024 quarter
- POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 3 quarters, 3.02K Cr → 3.54K Cr (in ₹), with an average increase of 7.6% per quarter
- POSITIVE IMPACT
MF Holding Up
Mutual Funds have increased holdings from 14.73% to 14.94% in Sep 2024 quarter
NO EFFECTAgainst Peers
In the last 1 year, Divis Laboratories Ltd has given 46.6% return, outperforming this stock by 42.9%
- NO EFFECT
Against Peers
In the last 3 years, Sun Pharmaceuticals Industries Ltd has given 103.2% return, outperforming this stock by 59.0%
NEGATIVE IMPACTPrice Dip
In the last 1 month, ALKEM stock has moved down by -4.0%
- NEGATIVE IMPACT
Retail Holding Down
Retail Investor have decreased holdings from 16.36% to 16.10% in Sep 2024 quarter
- NEGATIVE IMPACT
Promoter Holding Down
Promoters have decreased holdings from 56.38% to 55.66% in Sep 2024 quarter
Alkem Financials
Index Inclusions
Alkem Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 55.66% | ||
| Foreign Institutions | 9.02% | 3.80 | |
| Mutual Funds | 14.94% | 1.45 | |
| Retail Investors | 16.1% | ||
| Others | 4.27% | 10.99 |
Alkem Key Indicators
Alkem Valuation
Alkem in the last 5 years
Lowest (20.07x)
March 24, 2021
Today (29.61x)
January 17, 2025
Industry (54.95x)
January 17, 2025
Highest (44.21x)
August 9, 2023
Alkem Earnings and Dividends
Alkem Laboratories Ltd Earnings Results
Alkem Laboratories Ltd’s net profit jumped 10.98% since last year same period to ₹688.64Cr in the Q2 2024-2025. On a quarterly growth basis, Alkem Laboratories Ltd has generated 26.32% jump in its net profits since last 3-months.
Read More about Earnings ResultsAlkem Laboratories Ltd Dividends May,2024
In the quarter ending March 2024, Alkem Laboratories Ltd has declared dividend of ₹5 - translating a dividend yield of 0.76%.
Read More about Dividends
Alkem Technicals Summary
Bearish
Neutral
Bullish
Alkem Laboratories Ltd is currently in a Bearish trading position according to technical analysis indicators.
FAQs on Alkem Laboratories Ltd
Alkem Laboratories Ltd share price today stands at ₹5255.85, Open. ₹5192 ; Previous Close. ₹5181.8 ; High. ₹5283.5 ; Low. ₹5166.5 ; 52 Week High. ₹6439.9 ; 52 Week Low: ₹4407.05.
- Get a PAN card.
- Open a Demat account.
- Open a Trading account.
- Link your Demat account to your Trading account.
- Fund your Trading account.
- Place an order to buy Alkem Laboratories Ltd shares.
Alkem Laboratories Ltd is listed on NSE
Alkem Laboratories Ltd is listed on BSE
- Today’s highest price of Alkem Laboratories Ltd is ₹5283.5.
- Today’s lowest price of Alkem Laboratories Ltd is ₹5166.5.
PE Ratio of Alkem Laboratories Ltd is 29.61
PE ratio = Alkem Laboratories Ltd Market price per share / Alkem Laboratories Ltd Earnings per share
Today’s traded volume of Alkem Laboratories Ltd(ALKEM) is 74.86K.
Today’s market capitalisation of Alkem Laboratories Ltd(ALKEM) is ₹61956.19Cr.
| Alkem Laboratories Ltd(ALKEM | Price |
|---|---|
52 Week High | ₹6439.9 |
52 Week Low | ₹4407.05 |
Alkem Laboratories Ltd(ALKEM) share price is ₹5255.85. It is down -18.39% from its 52 Week High price of ₹6439.9
Alkem Laboratories Ltd(ALKEM) share price is ₹5255.85. It is up 19.26% from its 52 Week Low price of ₹4407.05
| Alkem Laboratories Ltd(ALKEM | Returns |
|---|---|
1 Day Returns | 74.05% |
1 Month Returns | -4.32% |
3 Month Returns | -14.3% |
1 Year Returns | 6.53% |